



February 04, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Dear Sir/Madam,

Subject: Confirmation on the news item appearing in Mainstream Media

This is with reference to the captioned subject and news item appearing in Mainstream Media today i.e. on February 04, 2025, titled "Lupin gets USFDA nod for generic HIC drug".

Pursuant to the Regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to confirm that the Company has received **tentative approval** from the U.S. FDA for its Abbreviated New Drug Application for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets, 800 mg/150 mg/200 mg/10 mg. The Company is the exclusive first-to-file for this product. This product will be manufactured at the Company's Nagpur facility in India.

As this event was not material as defined under Regulation 30 of the SEBI Listing Regulations, the same was not disclosed to the Stock Exchanges as required under the said Regulation.

Further, the Company is not aware of any other event or information that was required to be announced and has not been announced in terms of the Listing Regulations. The Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations and shall continue to do so.

You are requested to take the same on your record.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICE
(ACS -15754)

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com